Deucravacitinib is a medicine used to treat psoriasis and psoriatic arthritis. It is taken as a pill. It works by blocking a signal in the immune system that causes skin patches and joint swelling.
Every report comes from a Lived member, sent anonymously.
Have you tried Sotyktu (Deucravacitinib) for Psoriasis?
Deucravacitinib, sold as Sotyktu, is a once-a-day prescription pill for adults with two related immune conditions. It treats moderate-to-severe plaque psoriasis, the raised, scaly skin patches that cover a larger area of the body or are hard to control with creams, in adults whose disease calls for whole-body (systemic) treatment or light therapy (phototherapy). It is also approved for active psoriatic arthritis, the joint inflammation that affects some people with psoriasis and causes pain, swelling and stiffness. Many advanced treatments for these conditions are biologics given by injection or infusion, so deucravacitinib offers a tablet option at the same stage of care. It is not approved for children or for rheumatoid arthritis.
Psoriasis and psoriatic arthritis are driven by an overactive immune response. Immune messenger proteins called cytokines, including interleukin-23 (IL-23) and type I interferons, signal skin and joint tissue to become inflamed. Inside cells, these signals are passed along by enzymes in the Janus kinase (JAK) family. Deucravacitinib blocks one member of that family, tyrosine kinase 2 (TYK2), by locking it in an inactive shape. In people with psoriasis, it lowers the activity of IL-23 and interferon-related genes in affected skin, which tracks with calmer inflammation. Researchers do not yet know exactly how blocking TYK2 produces the improvement people see in their skin and joints.
Deucravacitinib comes as a single 6 mg tablet taken by mouth once a day, with or without food. The same dose is used for psoriasis and psoriatic arthritis. Swallow the tablet whole; do not crush, cut or chew it. Before the first dose, you will be tested for tuberculosis (TB). Anyone with a dormant (latent) TB infection starts TB treatment first, and people with active TB should not take it. Your prescriber will also want your routine vaccines up to date, including the shingles vaccine, before you start. It is not recommended for people with severe liver impairment.
The most common side effects in trials were colds and other upper respiratory infections (about 19% of people, compared with 15% on placebo), cold sores or other herpes simplex outbreaks, mouth ulcers, acne and folliculitis (small, pimple-like bumps around hair follicles). Most infections were mild to moderate. Blood tests may also show a raised level of creatine phosphokinase (CPK), an enzyme released by muscle, usually without any symptoms. Because it dampens part of the immune system, deucravacitinib can make infections more likely, including serious ones such as pneumonia and COVID-19, and can let shingles reactivate. Contact your care team promptly if you develop a fever, a cough that will not settle, a new painful rash or other signs of infection. Rarely, it has caused rhabdomyolysis, a breakdown of muscle tissue; report unexplained muscle pain, tenderness or weakness right away, especially if you also feel unwell or feverish. Swelling of the face, lips, tongue or throat can signal a serious allergic reaction; stop the medicine and get emergency care.
Deucravacitinib is not recommended together with other strong immune-suppressing medicines. Live vaccines should be avoided while you take it, so tell anyone vaccinating you that you are on it. In studies, it did not meaningfully affect, or get affected by, methotrexate (a long-used psoriasis and arthritis medicine), birth control pills or several other drugs tested, but your pharmacist should still review everything you take. It is generally not started during an active or serious infection, including active hepatitis B or C, and your prescriber may screen for hepatitis first. Cancers, including lymphoma, occurred in clinical trials, so tell your prescriber about any history of cancer. TYK2 belongs to the same enzyme family targeted by JAK inhibitor medicines. In a large study of a JAK inhibitor in people 50 and older with rheumatoid arthritis and at least one heart risk factor, there were more deaths, major heart and blood vessel events such as heart attack and stroke, blood clots and cancers than with a comparison treatment. It is not known whether deucravacitinib shares these risks. Its label has no boxed warning, but lists this as a possibility to weigh. People with diabetes should also report symptoms of low blood sugar, which has been reported after starting JAK inhibitors. Data on deucravacitinib in pregnancy and breastfeeding are too limited to judge the risk, so discuss pregnancy plans with your prescriber.
Improvement builds over the first few months. In one large psoriasis trial, 54% of people had clear or almost clear skin at week 16, compared with 7% on placebo and 32% on apremilast, another psoriasis pill, and more people responded by week 24. Scalp psoriasis also improved for many. In psoriatic arthritis trials, about 54% of people had at least a 20% improvement in joint measures at week 16, compared with 34 to 39% on placebo; fewer reached larger improvements, with roughly a quarter improving by 50% or more. The benefit lasts only while you keep taking it. When people whose skin had responded were switched to placebo, most lost that improvement, half of them within about 12 weeks, while about 80% of those who continued kept it at one year. Treatment is usually long-term, with periodic blood tests for triglycerides (a blood fat that can rise on this medicine) and liver tests if you have liver disease. If skin or joints have not improved enough after several months, your clinician may suggest a different treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Sotyktu (Deucravacitinib), what you've noticed, or ask the community a question.